197 related articles for article (PubMed ID: 33588260)
21. [Association Suvorexant and Ramelteon Use with the Risk of Falling: A Retrospective Case-control Study].
Ishigo T; Takada R; Kondo F; Ibe Y; Nakano K; Tateishi R; Fujii S; Katano S; Kitagawa M; Kimyo T; Nakata H; Hashimoto A; Miyamoto A
Yakugaku Zasshi; 2020; 140(8):1041-1049. PubMed ID: 32741862
[TBL] [Abstract][Full Text] [Related]
22. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
[TBL] [Abstract][Full Text] [Related]
23. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
[TBL] [Abstract][Full Text] [Related]
25. Real-World Effectiveness of Ramelteon and Suvorexant for Delirium Prevention in 948 Patients With Delirium Risk Factors.
Hatta K; Kishi Y; Wada K; Takeuchi T; Hashimoto N; Suda K; Taira T; Tsuchida K; Ohmori T; Akizuki N; Nishio Y; Nakanishi Y; Usui C; Kurata A; Horikawa N; Eguchi H; Ito S; Muto H; Nakamura H; Uchimura N
J Clin Psychiatry; 2019 Dec; 81(1):. PubMed ID: 31851436
[TBL] [Abstract][Full Text] [Related]
26. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Owen RT
Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
[TBL] [Abstract][Full Text] [Related]
27. Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia.
Wang-Weigand S; Watissée M; Roth T
Sleep Med; 2011 Oct; 12(9):920-3. PubMed ID: 21925941
[TBL] [Abstract][Full Text] [Related]
28. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826
[TBL] [Abstract][Full Text] [Related]
29. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty.
Mini LJ; Wang-Weigand S; Zhang J
Am J Geriatr Pharmacother; 2007 Sep; 5(3):177-84. PubMed ID: 17996657
[TBL] [Abstract][Full Text] [Related]
30. Preventive Effects of Ramelteon, Suvorexant, and Lemborexant on Delirium in Hospitalized Patients With Physical Disease: A Retrospective Cohort Study.
Henmi R; Nakamura T; Mashimoto M; Takase F; Ozone M
J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):369-377. PubMed ID: 38820374
[TBL] [Abstract][Full Text] [Related]
31. Ramelteon for Delayed Sleep-wake Phase Disorder: A Case Report.
Takeshima M; Shimizu T; Ishikawa H; Kanbayashi T
Clin Psychopharmacol Neurosci; 2020 Feb; 18(1):167-169. PubMed ID: 31958919
[TBL] [Abstract][Full Text] [Related]
32. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Morin CM; Lines C; Michelson D
Sleep Med; 2019 Apr; 56():219-223. PubMed ID: 30522875
[TBL] [Abstract][Full Text] [Related]
33. Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo.
Roehrs T; Withrow D; Koshorek G; Verkler J; Bazan L; Roth T
J Clin Sleep Med; 2020 Mar; 16(3):415-421. PubMed ID: 31992394
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic and pharmacodynamic evaluation of ramelteon : an insomnia therapy.
Spadoni G; Bedini A; Lucarini S; Mor M; Rivara S
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1145-56. PubMed ID: 25956235
[TBL] [Abstract][Full Text] [Related]
35. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
36. A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.
Edmonds C; Swanoski M
Consult Pharm; 2017 Mar; 32(3):156-160. PubMed ID: 28270270
[TBL] [Abstract][Full Text] [Related]
37. Profile of suvorexant in the management of insomnia.
Sutton EL
Drug Des Devel Ther; 2015; 9():6035-42. PubMed ID: 26648692
[TBL] [Abstract][Full Text] [Related]
38. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.
Sun H; Kennedy WP; Wilbraham D; Lewis N; Calder N; Li X; Ma J; Yee KL; Ermlich S; Mangin E; Lines C; Rosen L; Chodakewitz J; Murphy GM
Sleep; 2013 Feb; 36(2):259-67. PubMed ID: 23372274
[TBL] [Abstract][Full Text] [Related]
39. Suvorexant with or without ramelteon to prevent delirium: a systematic review and meta-analysis.
Tian Y; Qin Z; Han Y
Psychogeriatrics; 2022 Mar; 22(2):259-268. PubMed ID: 34881812
[TBL] [Abstract][Full Text] [Related]
40. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
Kuriyama A; Tabata H
Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
